Transferases

GERI-BP002-A is an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor derived from Aspergillus fumigatus F93. This compound is primarily utilized in cancer research, where it plays a crucial role in studying lipid metabolism and its impact on tumor progression. By inhibiting ACAT, GERI-BP002-A contributes to the alteration of cholesterol esters, facilitating investigations into lipid-related pathways in various cancer models.

Terpendole C is a potent acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor derived from Albophoma yamanashiensis. This compound exhibits significant biological activity in modulating lipid metabolism by inhibiting the conversion of cholesterol to cholesteryl esters. Terpendole C is widely utilized in research focusing on cholesterol-related disorders and lipid metabolism studies.

Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor that exhibits hypocholesterolemic activity. Isolated from the seeds of Zingiberaceae, it specifically inhibits rat hepatic ACAT with an IC50 value of 20.6 μM. This compound holds potential for research applications related to hypercholesterolemia and atherosclerosis, contributing to the understanding of cholesterol metabolism and cardiovascular health.

LDL-IN-1 is a potent antioxidant that effectively inhibits copper-mediated LDL oxidation, with an IC50 of 52 µM. Additionally, it serves as an inhibitor of Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2), exhibiting IC50 values of 60 µM. This compound is valuable for research into anti-atherosclerotic mechanisms and the modulation of cholesterol metabolism.

TMP-153 is a potent inhibitor of Acyl-CoA:cholesterol acyltransferase (ACAT) with an IC50 value ranging from 5-10 nM for hepatic and intestinal ACAT, demonstrated in preclinical studies. This compound effectively reduces cholesterol levels and is primarily utilized in research related to atherosclerosis and lipid metabolism. TMP-153's mechanism of action makes it a valuable tool for studying cholesterol-related disorders and their potential therapeutic interventions.

S-309309 is a selective inhibitor of MGAT2, an enzyme involved in glycan biosynthesis. This compound demonstrates oral bioactivity and has potential applications in metabolism-related research, particularly in the study of lipid metabolism and its implications in metabolic disorders. S-309309 may serve as a valuable tool for investigating the role of MGAT2 in cellular pathways and metabolic regulation.

2,6-Dichlorophenylacetic acid acts as an inhibitor of isopenicillin N synthase (IPNS) and acyl-CoA: 6-APA acyltransferase. This compound exhibits notable cytostatic activity against tumor cells, making it a valuable tool in cancer research. Its role in modulating bacterial cell wall biosynthesis positions it as a relevant agent for studying antibiotic mechanisms and drug development.

C12-Sphingosine is a short-chain sphingosine homologue that primarily targets serine palmitoyltransferase. This reagent is known to inhibit the activity of this enzyme in primary cultured cerebellar cells, making it valuable for studying sphingolipid metabolism and its implications in neurobiology. Its applications extend to exploring cellular signaling pathways and understanding the role of sphingolipids in various physiological and pathological processes.

OSMI-3 is a selective inhibitor of O-linked N-acetylglucosamine transferase (OGT), characterized by its potent and cell-permeable properties. This compound effectively modulates OGT activity, leading to the enhancement of retained intron splicing in cellular contexts. OSMI-3 is valuable in research investigating the role of OGT in cellular processes and its implications in various disease states.

ANAT inhibitor-1 is a selective inhibitor of human aspartate N-acetyltransferase (ANAT), specifically developed for research into canavan disease. By inhibiting ANAT, this compound plays a crucial role in studying the biochemical pathways disrupted in this disorder. Its application extends to elucidating the mechanisms underlying neurodegenerative conditions and developing potential therapeutic strategies.

ST1060 is a selective ceramide synthase 2 (CerS2) inhibitor. It effectively reduces the levels of long-chain dihydroceramide (dhCer) with IC50 values of 63.6 μM and 61.3 μM for C24:0 and C24:1, respectively. This compound is valuable for research applications involving lipid metabolism, cellular stress responses, and potential therapeutic strategies targeting sphingolipid pathways.

Eldacimibe is an inhibitor of acyl-CoA:cholesterol acyltransferase 2 (ACAT2), which plays a crucial role in cholesterol metabolism. This compound effectively reduces plasma cholesterol levels by inhibiting cholesterol absorption and preventing the transformation of macrophages into foam cells. Eldacimibe is applicable in research focused on cardiovascular diseases such as atherosclerosis, as well as endocrine and metabolic disorders, particularly hypercholesterolemia.

CP-316819 is a potent inhibitor of glycogen phosphorylase (GPase), demonstrating significant antihyperglycemic activity with IC50 values of 17 nM and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa), respectively. This compound promotes glycogen accumulation under normoglycemic conditions while allowing glycogen utilization during low glucose availability. Additionally, CP-316819 has been shown to prevent neuronal cell death and sustain brain electrical activity, making it a valuable tool for research into metabolic regulation and neuroprotection.

Glycogen phosphorylase-IN-1 is a potent inhibitor of human liver glycogen phosphorylase (hlGPa), demonstrating IC50 values of 53 nM for the enzyme and 380 nM for glucose production from hepatocyte glycogen. This compound is particularly relevant for research applications targeting type 2 diabetes, as it effectively reduces glycogen-derived glucose production in hepatocytes, thereby influencing glucose homeostasis.

BAY R3401 is an orally active inhibitor of glycogen phosphorylase, demonstrating irreversible and non-selective inhibition of hepatic glycogenolysis. This compound effectively inhibits glycogenolysis in liver cells, exhibiting IC50 values of 27.06 μM in HL-7702 cells and 52.83 μM in HepG2 cells. BAY R3401 serves as a valuable tool for research focused on type 2 diabetes and its associated metabolic pathways.

GPi688 is a potent and orally active inhibitor of glycogen phosphorylase (GPa), demonstrating IC50 values of 19 nM, 61 nM, and 12 nM for human liver GPa, rat liver GPa, and human skeletal muscle GPa, respectively. This compound effectively inhibits glucagon-mediated glucose output in rat primary hepatocytes. GPi688 is a valuable tool for investigating glucagon-mediated hyperglycemia and related metabolic disorders in research applications.

Deoxyadenosine diphosphate sodium is a nucleoside diphosphate that functions as a phosphorylase inhibitor. It plays a crucial role in DNA synthesis and repair processes by inhibiting polynucleotide phosphorylase, thereby interfering with the polymerization of ADP and CDP. This compound is valuable for research applications focused on understanding DNA metabolism and enzymatic regulation in cellular systems.

GGTI-2147 is a potent inhibitor of geranylgeranyl transferase I (GGTase I). It effectively blocks the geranyl-geranylation of the small GTPase Rap1A, leading to a reduction in Rac1 activity and mitigation of OGD/R-induced neuronal apoptosis. This compound is valuable for research into neurodevelopmental disorders, including autism, depression, and schizophrenia.

TK-112690 is a selective inhibitor of uridine phosphorylase 1 (UPP1). It demonstrates inhibitory effects on murine small intestinal uridine phosphorylase with an IC50 of 12.5 μM and on human small intestinal UPP1 with an IC50 of 20.0 μM in vitro. By increasing plasma uridine concentration in mice, TK-112690 can be utilized to explore therapeutic avenues in cancer research and pulmonary fibrosis studies.